Clinical Trials

The Cutaneous Lymphoma Foundation provides information about clinical trials to help move new treatments forward. There may be clinical trials available that we are not aware of. To find additional trials, visit clinicaltrials.gov. Keep in mind that many sponsors of clinical trials cover transportation and other costs for patient participation so we encourage you to consider trials that may not be close to you.

STUDY OF COBOMARSEN IN PATIENTS WITH MYCOSIS FUNGOIDES (SOLAR)

The main objective of this clinical trial is to study the efficacy and safety of cobomarsen (also known as MRG-106) for the treatment of cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) subtype.

STUDY OF COBOMARSEN IN PATIENTS WITH MYCOSIS FUNGOIDES (SOLAR)

The main objective of this clinical trial is to study the efficacy and safety of cobomarsen (also known as MRG-106) for the treatment of cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) subtype.

STUDY OF COBOMARSEN IN PATIENTS WITH MYCOSIS FUNGOIDES (SOLAR)

The main objective of this clinical trial is to study the efficacy and safety of cobomarsen (also known as MRG-106) for the treatment of cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) subtype.

STUDY OF COBOMARSEN IN PATIENTS WITH MYCOSIS FUNGOIDES (SOLAR)

The main objective of this clinical trial is to study the efficacy and safety of cobomarsen (also known as MRG-106) for the treatment of cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) subtype.

STUDY OF COBOMARSEN IN PATIENTS WITH MYCOSIS FUNGOIDES (SOLAR)

The main objective of this clinical trial is to study the efficacy and safety of cobomarsen (also known as MRG-106) for the treatment of cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) subtype.

STUDY OF COBOMARSEN IN PATIENTS WITH MYCOSIS FUNGOIDES (SOLAR)

The main objective of this clinical trial is to study the efficacy and safety of cobomarsen (also known as MRG-106) for the treatment of cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) subtype.

STUDY OF COBOMARSEN IN PATIENTS WITH MYCOSIS FUNGOIDES (SOLAR)

The main objective of this clinical trial is to study the efficacy and safety of cobomarsen (also known as MRG-106) for the treatment of cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) subtype.

STUDY OF COBOMARSEN IN PATIENTS WITH MYCOSIS FUNGOIDES (SOLAR)

The main objective of this clinical trial is to study the efficacy and safety of cobomarsen (also known as MRG-106) for the treatment of cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) subtype.

STUDY OF COBOMARSEN IN PATIENTS WITH MYCOSIS FUNGOIDES (SOLAR)

The main objective of this clinical trial is to study the efficacy and safety of cobomarsen (also known as MRG-106) for the treatment of cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) subtype.

STUDY OF COBOMARSEN IN PATIENTS WITH MYCOSIS FUNGOIDES (SOLAR)

The main objective of this clinical trial is to study the efficacy and safety of cobomarsen (also known as MRG-106) for the treatment of cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) subtype.

STUDY OF COBOMARSEN IN PATIENTS WITH MYCOSIS FUNGOIDES (SOLAR)

The main objective of this clinical trial is to study the efficacy and safety of cobomarsen (also known as MRG-106) for the treatment of cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) subtype.

STUDY OF COBOMARSEN IN PATIENTS WITH MYCOSIS FUNGOIDES (SOLAR)

The main objective of this clinical trial is to study the efficacy and safety of cobomarsen (also known as MRG-106) for the treatment of cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) subtype.

United States

Safety and Efficacy Study of a Dual Pi3k Delta/Gamma Inhibitor in T-Cell Lymphoma

The purpose of this study is to evaluate the safety, PK and efficacy of RP6530, a dual PI3K delta/gamma inhibitor in patients with relapsed and refractory T-cell Lymphoma.

STUDY OF COBOMARSEN IN PATIENTS WITH MYCOSIS FUNGOIDES (SOLAR)

The main objective of this clinical trial is to study the efficacy and safety of cobomarsen (also known as MRG-106) for the treatment of cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) subtype.